Healx vs Paige AI

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Healx employs 1-50 people, while Paige AI has 100-500 employees.

Paige AI has raised more in total funding at $125M, compared to Healx's $47M — a gap of $78M.

Paige AI holds the higher Awaira Score at 65/100, compared to Healx's 55/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 10-point gap that reflects meaningful differences in scale or traction.

Healx was founded by Tim Guilliams in 2014. Paige AI was founded by Leo Grady in 2018. Visit each company's profile on Awaira for a full founder biography.

Healx: Healx uses AI to identify and develop treatments for rare diseases, applying graph neural networks and multi-omics data analysis to repurpose existing approved drugs for new orphan disease indications. The Cambridge-based company focuses exclusively on rare diseases, where the small patient populations and limited existing literature make traditional drug discovery economically unviable without computational approaches that can extract signal from sparse data.\n\nThe company raised a $47 million Series B led by Balderton Capital and includes strategic investors from the rare disease patient advocacy community. Healx has assembled a pipeline of repurposing candidates for conditions including Fragile X syndrome, tuberous sclerosis complex, and other rare neurodevelopmental disorders, with several candidates advancing into clinical studies. The company partners with patient advocacy groups to access natural history data and patient registries that inform its disease models.\n\nHealx operates in a rare disease AI market that is less crowded than oncology-focused drug discovery AI but equally challenging due to regulatory complexity and small trial populations. The company competes with Healios, BenevolentAI, and specialist rare disease biotechs that are increasingly adopting computational methods. Its exclusive focus on rare diseases and its community partnerships represent a defensible niche that larger generalist AI drug discovery platforms have not prioritised. Paige AI: Paige AI develops AI-powered pathology software that assists pathologists in identifying cancer and other diseases in digital whole-slide images. The platform received the first-ever FDA authorization for an AI-based primary diagnostic tool in pathology, a milestone that establishes regulatory precedent for clinical AI deployment in histopathology workflows.\n\nThe company raised approximately 125 million USD and partners with major academic medical centers and pathology laboratories to integrate its diagnostic AI into clinical workflows. Paige has expanded beyond prostate cancer detection into additional cancer types and is building a multi-cancer detection platform intended to function as a comprehensive AI layer across pathology departments.\n\nDigital pathology combined with AI represents one of the clearest near-term commercialization opportunities in medical AI, as the transition from glass slides to whole-slide imaging creates a digital substrate that AI can operate on at scale. Paige FDA clearance creates a significant regulatory moat that competitors must match before selling comparable diagnostic tools in the US market, giving the company a durable first-mover advantage in the AI-augmented pathology workflow.

Healx was founded first in 2014, giving it 4 years of additional market experience. Paige AI was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Healx has approximately 1-50 employees, while Paige AI has approximately 100-500. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Healx and Paige AI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.